332 related articles for article (PubMed ID: 35255942)
1. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
2. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
3. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
[TBL] [Abstract][Full Text] [Related]
4. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
5. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
8. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
[TBL] [Abstract][Full Text] [Related]
9. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
10. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
[TBL] [Abstract][Full Text] [Related]
11. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
12. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
13. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
Cirello V
Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
[TBL] [Abstract][Full Text] [Related]
14. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
15. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
16. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
17. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
[TBL] [Abstract][Full Text] [Related]
18. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
19. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
Diquigiovanni C; Bonora E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
[TBL] [Abstract][Full Text] [Related]
20. Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.
Mohammadi Zaniani Z; Zeinalian M; Tabatabaiefar MA
Lab Med; 2023 Nov; ():. PubMed ID: 38007399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
